Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial

Heart and Lung: Journal of Acute and Critical Care

Volumn 32, Issue 1, 2003, Pages 3-9

  Ekman, Inger ^a,b   Fagerberg, Björn ^a   Andersson, Björn ^a   Matejka, Göran ^a   Persson, Bengt ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; LISINOPRIL; NITRIC ACID DERIVATIVE; RAMIPRIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NURSING; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0037255521     PISSN: 01479563     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhl.2003.5     Document Type: Article

References (21)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enlalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
3. Ritchie JL, Cheitlin MD, Eagle KA, et al. Guidelines for the evaluation and management of heart failure. Report of the American college of Cardiology/American Heart Association Task Force on practice guidelines (Committee on evaluation and management of heart failure). Circulation 1995;92:2764-84.
4. Task force of the Working Group on Heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
5. Swedberg K, Sharpe N. The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after myocardial infarction. Eur Heart J 1996;17:1306-11.
6. Bourassa MG, Gurne O, Bangdiwala SI, et al, for the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(Suppl A):14A-19A.
7. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
8. Clinical Quality Improvement Network investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Arch Intern Med 1996;156:1669-73.
9. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor undertutilization in heart failure in a community setting. Clin Cardiol 1998;21:103-8.
10. Clarke KE, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71:584-7.
11. Eriksson H. Heart failure: a major public health problem. In: Andrén L. Beerman B. Benson L, et al. editors. Pharmacological treatment of heart failure. Uppsala: Swedish Medical Products Agency; 1993. p. 7-19.
12. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse-monitored, outpatient care-program for elderly patients with moderate-to-severe, chronic heart failure Eur Heart J 1998;19:1254-60.
13. Carlson KJ, Lee DC, Goroll AH, Lehay M, Johnson RA. An analysis of physicians' reasons fo prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985;38:733-9.
14. Ljungman S, Kiekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril. Results of the Cooperative North Scandinavian Enlalapril Survival Study (CONSENSUS). Am J Cardiol 1992;70:479-87.
15. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
16. Nanas IN, Alexopoulos G, Anastasia-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 2000;36:2090-5.
17. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998; 82:465-9.
18. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose age inhibition in chronic heart failure. J Am Coll Cardiol 1998;32:1811-8.
19. Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibitation and angiotensin-II antagonism. J Am Coll Cardiol 1999;33:1163-73.
20. O'Keefe S, Lye MDW. Heart failure in the elderly: the same syndrome as the clinical trials? In: McMurray JJV, Cleland JGF, editors. Heart failure in clinical practice. London: Martin Dunez; 1996. p. 47-71.
21. Philbin EF, Rocco TA Jr. Use of angiogensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134:188-95.